Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cortoss enters kyphoplasty trial in US:

This article was originally published in Clinica

Executive Summary

Orthovita is to begin a second pilot clinical study to evaluate its Cortoss synthetic cortical bone void filler in the treatment of vertebral compression fractures (VCF) using a treatment technique called kyphoplasty. During kyphoplasty, an inflatable bone tamp is used to reduce the fracture and create a void in which the CORTOSS biomaterial can be injected. In January 2003, Orthovita began its first US pilot clinical study of CORTOSS for treating VCF using the vertebroplasty technique, whereby the biomaterial is injected without using the inflatable device. In the same month, the Malvern, Pennsylvania firm gained European approval to market the product for vertebral augmentation, including the repair of VCF.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel